Leukocyte interleukin, INJ. (LI) augmentation of natural killer cells and cytolytic t-lymphocytes

M. A. Chirigos, E. Talor, R. W. Sidwell, R. A. Burger, R. P. Warren

Research output: Contribution to journalArticle


A serum free lymphokine preparation derived from human buffy-coat mononuclear cells [buffy coat interleukins (BC-IL)], also named Leukocyte Interleukin, Inj. (LI), trade name Multikine™ containing glycosylated interleukin-2 (IL-2) among other interleukins, was tested in three head and neck cancer patients. They responded with tumor regressions associated with increased tumor infiltration of lymphocytes and tumor cell lysis indicating an LI Interleukin-2 induced tumor-specific immune response. to determine whether these responses elicited by LI were IL-2 driven, augmentation of natural killer cells (NKC) and cytolytic T cells (CTL), was tested both in vitro and in vivo. A single intraperitoneal (ip) injection of LI in adult BALB/c mice at doses of 3, 10, 30 and 100 of IL-2 equivalence International Units per mouse, led to significant (p intraperitoneal(ip) > intramuscular(im) >subcutaneous(sc). Significant (p

Original languageEnglish (US)
Pages (from-to)247-264
Number of pages18
JournalImmunopharmacology and Immunotoxicology
Issue number2
StatePublished - 1995
Externally publishedYes

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Pharmacology
  • Toxicology
  • Health, Toxicology and Mutagenesis

Fingerprint Dive into the research topics of 'Leukocyte interleukin, INJ. (LI) augmentation of natural killer cells and cytolytic t-lymphocytes'. Together they form a unique fingerprint.

  • Cite this